Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Leukemia cell lines

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Antibiotic (2) Apoptosis (28) Aurora Kinase (1) Autophagy (3) Bacterial (1) Bcl-2 Family (3) Bcr-Abl (2) Biochemical Assay Reagents (1) c-Myc (1) Carbonic Anhydrase (1) Caspase (3) CDK (1) DNA Methyltransferase (2) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (1) Endogenous Metabolite (2) Epigenetic Reader Domain (3) Eukaryotic Initiation Factor (eIF) (1) Farnesyl Transferase (1) Ferroptosis (1) FLT3 (9) GSK-3 (1) HDAC (3) Histone Acetyltransferase (1) Histone Demethylase (2) Histone Methyltransferase (2) HSV (1) Isocitrate Dehydrogenase (IDH) (2) Lipoxygenase (1) MDM-2/p53 (1) Microtubule/Tubulin (1) Molecular Glues (1) mTOR (1) Parasite (2) Phosphatase (1) Phospholipase (1) PI3K (2) Pim (1) Polo-like Kinase (PLK) (5) PROTACs (3) Reactive Oxygen Species (1) Ser/Thr Kinase (1) Sirtuin (2) SphK (1) STAT (2) Syk (2) TMV (1) Topoisomerase (1) Transferrin Receptor (1) Trk Receptor (1) WDR5 (1)
By Research Areas:	Cancer (78) Infection (6) Inflammation/Immunology (1)

By Targets:

AMPK (1)

Antibiotic (2)

Apoptosis (28)

Aurora Kinase (1)

Autophagy (3)

Bacterial (1)

Bcl-2 Family (3)

Bcr-Abl (2)

Biochemical Assay Reagents (1)

c-Myc (1)

Carbonic Anhydrase (1)

Caspase (3)

CDK (1)

DNA Methyltransferase (2)

DNA/RNA Synthesis (1)

E1/E2/E3 Enzyme (1)

E3 Ligase Ligand-Linker Conjugates (1)

EGFR (1)

Endogenous Metabolite (2)

Epigenetic Reader Domain (3)

Eukaryotic Initiation Factor (eIF) (1)

Farnesyl Transferase (1)

Ferroptosis (1)

FLT3 (9)

GSK-3 (1)

HDAC (3)

Histone Acetyltransferase (1)

Histone Demethylase (2)

Histone Methyltransferase (2)

HSV (1)

Isocitrate Dehydrogenase (IDH) (2)

Lipoxygenase (1)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

Molecular Glues (1)

mTOR (1)

Parasite (2)

Phosphatase (1)

Phospholipase (1)

PI3K (2)

Pim (1)

Polo-like Kinase (PLK) (5)

PROTACs (3)

Reactive Oxygen Species (1)

Ser/Thr Kinase (1)

Sirtuin (2)

SphK (1)

STAT (2)

Syk (2)

TMV (1)

Topoisomerase (1)

Transferrin Receptor (1)

Trk Receptor (1)

WDR5 (1)

By Research Areas:

Cancer (78)

Infection (6)

Inflammation/Immunology (1)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: BMI1 Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor VISTA BCL6 Tim3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N7634

Tectol	Farnesyl Transferase Parasite	Infection Cancer
Tectol, isolated from Lippia sidoides, exhibits significant activity against human leukemia cell lines HL60 and CEM . Tectol is a farnesyltransferase (FTase) inhibitor with IC₅₀s of 2.09 and 1.73 μM for human and T. brucei FTase, respectively. Tectol inhibits drug-resistant strain of P. falciparum (FcB1) with an IC₅₀ of 3.44 μM .

HY-148422

Rohinitib	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML .

HY-N0128

Sclareol 1 Publications Verification	Apoptosis	Cancer
Sclareol is isolated from Salvia sclarea with anticarcinogenic activity. Sclareol shows strong cytotoxic activity against mouse leukemia?(P-388), human epidermal?carcinoma?(KB) cells and human?leukemia?cell lines. Sclareol induces cell apoptosis .

HY-148026

Sonrotoclax BGB 11417	Bcl-2 Family	Cancer
Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines .

HY-144675

LSD1-IN-13	Histone Demethylase	Cancer
LSD1-IN-13 (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines .

HY-144675A

LSD1-IN-13 hydrochloride	Histone Demethylase	Cancer
LSD1-IN-13 hydrochloride (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 hydrochloride can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 hydrochloride induces differentiation of AML (acute myeloid leukemia) cell lines .

HY-113700

PD 116779	Antibiotic	Cancer
PD 116779 is an Antibiotic with anticancer activity. PD 116779 demonstrates moderate cytotoxicity against L1210 lymphocytic leukemia and HCT-8 human colon adenocarcinoma cell lines with IC₅₀ values of 3.55x10 ^-7 and 4.08x10 ^-7 M, respectively .

HY-121352

Kibdelone C	Others
Kibdelone C is a flavonoid compound found in Kibdelosporangium sp. with anticancer activity, exhibiting GI₅₀ values of less than 1 nM against leukemia cell lines (SR) and renal cancer cell lines (SN12C). Kibdelone C is promising for anticancer research .

HY-N0128R

Sclareol (Standard)	Apoptosis	Cancer
Sclareol (Standard) is the analytical standard of Sclareol. This product is intended for research and analytical applications. Sclareol is isolated from Salvia sclarea with anticarcinogenic activity. Sclareol shows strong cytotoxic activity against mouse leukemia (P-388), human epidermal carcinoma (KB) cells and human leukemia cell lines. Sclareol induces cell apoptosis .

HY-155557

Anti-inflammatory agent 45	Apoptosis	Cancer
Anti-inflammatory agent 45 (compound 2v) is an anticancer agent with direct inhibitory effects on the growth of different blood cancers including leukemia, lymphoma and myeloma cell lines. Anti-inflammatory agent 45 induces apoptosis and inhibits NO production in HL60 leukemia cells (IC₅₀=14.7 μM) .

HY-119594

Melarsoprol	Parasite	Infection
Melarsoprol, a melaminophenylarsine-type trivalent organic arsenical, is an important drug for African trypanosomiasis. Melarsoprol is also active against leukemia cell lines and plasma cells from myeloma patients. Melarsoprol increases the biliary output of GSH in rats .

HY-115406A

CPTH6 hydrobromide	Apoptosis	Cancer
CPTH6 hydrobromide is a thiazole derivative which activates apoptotic program and increases autophagic features in human acute myeloid leukemia cell lines. CPTH6 can be used for cancer research .

HY-149896

Antitumor agent-107	Biochemical Assay Reagents	Cancer
Antitumor agent-107 (compound 5h) is an anticancer agent that shows excellent inhibitory activity against leukemia cell lines (GI₅₀=0.32-1.34 μM). Antitumor agent-107 also shows antitumor activity against various other human cancer cell lines (GI₅₀ range 0.35-9.43 μM) .

HY-129983

5-Hydroxymethyl-2'-deoxyuridine	HSV	Infection Cancer
5-Hydroxymethyl-2'-deoxyuridine is a nucleoside analog. 5-Hydroxymethyl-2'-deoxyuridine inhibits the replication of multiple human leukemia cell lines with IC₅₀ values of 1.7-5.8 μM. 5-Hydroxymethyl-2'-deoxyuridine prolongs the survival of mice carrying L1210 leukemia. 5-Hydroxymethyl-2'-deoxyuridine can be used for the research of cell replication and leukemia .

HY-103275

Adaphostin NSC 680410	Bcr-Abl Apoptosis	Cancer
Adaphostin (NSC 680410), the adamantyl ester of AG957, is a potent p210 ^bcr/abl inhibitor (IC₅₀=14 μM). Adaphostin induces apoptosis in T-lymphoblastic human leukemia cell lines (IC₅₀ ranging from 17 to 216 nM). Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Adaphostin increased the level of reactive oxygen species (ROS) within CLL B cells .

HY-149912

CZS-241	Polo-like Kinase (PLK) Trk Receptor Apoptosis	Cancer
CZS-241 is an orally active and selective inhibitor of Polo-like Kinase (PLK) 4 (IC₅₀=2.6 nM). CZS-241 inhibits TRKA with an IC₅₀ value of 2.74 μM. CZS-241 induces apoptosis and arrests cell cycle at S/G2 phase. CZS-241 shows highly potent antiproliferative activity against leukemia cell lines, and exhibits safety against normal cell lines .

HY-W267446

6-Methoxy-4-methylcoumarin	Others	Cancer
6-Methoxy-4-methylcoumarin is an ether compound containing a substituted benzylamino group, exhibiting antitumor activity, and can inhibit the growth of cell lines such as leukemia cell line HL-60, lung cancer, bladder cancer, prostate cancer, and rectal cancer .

HY-N10364

6β,7β-Epoxyasteriscunolide A	Others	Cancer
6β,7β-Epoxyasteriscunolide A, a sesquiterpenoid, shows cytotoxicity against the HL-60 and MOLT-3 leukemia cell lines, with IC₅₀s range 4.1-5.4 μM .

HY-167671

BE-10988	Topoisomerase	Cancer
BE-10988 is a DNA topoisomerase inhibitor. BE-10988 inhibits the growth of Doxorubicin (HY-15142A)-resistant and vincristine-resistant P388 mouse leukemia cell lines by increasing the formation of DNA topoisomerase complexes .

HY-12458

Pyrindamycin A	DNA/RNA Synthesis	Infection Cancer
Pyrindamycin A is an antibiotic that inhibits DNA synthesis. Pyrindamycin A shows antitumor activities against murine leukemia, exhibits stronger cytotoxic activities towards murine and human tumor cell lines and especially towards doxorubicin-resistant cells, inhibits P388 and P388/ADR cells with the same IC₅₀ of 3.9 μg/ml .

HY-152133

PROTAC HDAC6 degrader 1	PROTACs HDAC Apoptosis	Cancer
PROTAC HDAC6 degrader (Compound A6) is a potent and selective PROTAC HDAC6 degrader with a DC₅₀ of 3.5 nM. PROTAC HDAC6 degrader shows promising antiproliferative activity via inducing apoptosis in myeloid leukemia cell lines .

HY-121412

Lankacidin C	Antibiotic Bacterial	Infection Cancer
Lankacidin C is an inhibitor of protein synthesis in vitro. Lankacidin C inhibits the activity of L1210 leukemia, B16 melanoma and 6C3 HED/OG lymphosarcoma cell lines. Lankacidin C has antibacterial activity and antitumor activity .

HY-161516

HDAC6-IN-42	HDAC	Cancer
HDAC6-IN-42 (compound 2b) is an HDAC6 inhibitor (IC₅₀=0.009 μM). HDAC6-IN-42 shows significant anti-leukemia activity and synergistic effect with Decitabine (HY-A0004). HDAC6-IN-42 can be used for the AML research .

HY-120187

DDCPPB-Glu	Others	Others
DDCPPB-Glu (compound 3a) is a compound with anti-tumor activity, which has the activity of inhibiting tumor cell growth and prolonging survival. DDCPPB-Glu has growth inhibition effect on various tumor cell lines, can increase the survival time of leukemia mice, and has inhibitory effect on tumors such as colon cancer and lung cancer.

HY-12892

SKI-178	SphK Apoptosis	Cancer
SKI-178 is a potent sphingosine kinase-1 (SphK1) and SphK2 inhibitor. SKI-178 is cytotoxic at IC₅₀ concentrations ranging from 1.8 to 0.1 μM in both agent sensitive and multi-agent resistant cancer cell lines (i.e., MTR3, NCI-ADR and HL60/VCR cells). SKI-178 induces apoptosis in a CDK1-dependent manner in human acute myeloid leukemia cell lines .

HY-150025

(4aS,8aR)-NPD-001	DNA Methyltransferase Apoptosis	Cancer
(4aS,8aR)-NPD-001 is a potent and allosteric inhibitor of DNMT3A. (4aS,8aR)-NPD-001 inhibits DNMT3A activity by disrupting protein-protein interactions. (4aS,8aR)-NPD-001 induces apoptosis of acute myeloid leukemia (AML) cell lines. (4aS,8aR)-NPD-001 induces differentiation of distinct AML cell lines including cells with mutated DNMT3A R882 .

HY-121725

MM-206	STAT	Cancer
MM-206, a STAT3 activity inhibitor, potently inhibits the STAT3 SH2 domain-phosphopeptide interaction with IC₅₀ of 1.2 μM. MM-206 demonstrates dose-dependent induction of apoptosis in acute myeloid leukemia (AML) cell lines .

HY-143247

Tubulin polymerization-IN-2	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-2 is a potent anticancer agent targeting to β-tubulin with an IC₅₀ value of 0.92 μM. Tubulin polymerization-IN-2 shows promising activity against various leukemia, non-small lung, renal, prostate, and breast cancer cell lines .

HY-170574

CQ627	Molecular Glues Ser/Thr Kinase Apoptosis	Cancer
CQ627 is a molecular glue targeting the degradation of RIOK2. It effectively induces the degradation of RIOK2 in the MOLT4 leukemia cell line via the ubiquitin-proteasome system (UPS) by recruiting the E3 ubiquitin ligase RNF126, with a DC₅₀ value of 410 nM. CQ627 dose-dependently induces apoptosis in MOLT4 leukemia cells, blocks their cell cycle in the G2/M phase, and exhibits antiproliferative activities in various cancer cell lines. CQ627 also demonstrates in vivo anticancer activity in a MOLT4 xenograft mouse model .

HY-114162B

VTP50469 mesylate	Others	Cancer
VTP50469 mesylate is a potent, and selective Menin-MLL1 inhibitor that effectively targets MLL-rearranged and NPM1c+ leukemia. VTP50469 mesylate selectively kills cell lines with MLL rearrangements and NPM1c+ mutations. VTP50469 mesylate displaces Menin from protein complexes and inhibits MLL's chromatin occupancy at specific genes, leading to significant changes in gene expression, differentiation, and apoptosis. VTP50469 demonstrates dramatic reductions in leukemia burden in patient-derived xenograft models of MLL-r acute myeloid leukemia and MLL-r acute lymphoblastic leukemia, with some mice remaining disease-free for over a year post-treatment.

HY-161123

WDR5-IN-8	WDR5	Cancer
WDR5-IN-8 is a WDR5 inhibitor with IC₅₀ value of 15.5 nM. WDR5-IN-8 shows good anti-proliferative activity in two human acute leukemia cell lines. WDR5-IN-8 has antitumor activity .

HY-N10777

1-Ketoaethiopinone	Others	Cancer
1-Ketoaethiopinone is an abietane-diterpenoid. 1-Ketoaethiopinone has an α, β-unsaturated carbonyl function. 1-Ketoaethiopinone shows cytotoxic activity against human cancer cell lines MOLT-4 (human lymphoblastic leukemia) and MCF-7 (human breast adenocarcinoma) .

HY-162265A

UCM-13369 dihydrochloride	Apoptosis	Cancer
UCM-13369 (Compound 4b) is a NPM1 inhibitor. UCM-13369 downregulates the pathway associated with mutant NPM1 C+, and specifically recognizes the C-end DNA-binding domain of NPM1 C+. UCM-13369 induces apoptosis in AML cell lines and primary cells. UCM-13369 can be used for leukemia research .

HY-167860

BE-12406B	Others	Cancer
BE-12406B is an antitumor agent that can be found in the culture broth of a streptomycete. BE-12406B can inhibit the growth of Vincristine (HY-N0488)-resistant or Doxorubicin (HY-15142A)-resistant P388 murine leukemia cell lines as well as their parent sensitive cell line .

HY-15160

TAK-960 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-15160B

TAK-960 dihydrochloride 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-15160A

TAK-960 hydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 hydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 hydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 hydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-15160C

TAK-960 monohydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 monohydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 monohydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 monohydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-162037

CDDD11-8	CDK FLT3	Cancer
CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with K_i values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation .

HY-163160

BET-IN-23	Apoptosis Epigenetic Reader Domain	Cancer
Bet-in-23 (Compound 23) is a BD2-selective BET inhibitor with an IC₅₀ of 2.9 nM. BET-IN-23 has anticancer activity and can significantly inhibit the proliferation of acute myeloid leukemia (AML) cell lines by inducing G0/G1 arrest and apoptosis in vitro .

HY-155522

WES-1	Carbonic Anhydrase	Cancer
WES-1 (Compound 8g) is an inhibitor of carbonic anhydrase IX (K_i: 55.9 μM). WES-1 has broad spectrum anti-proliferative activity against the cancer cells, such as leukemia (K-562 and MOLT-4), non-small cell lung cancer (NCI–H460), colon cancer (HCT 116 and HCT-15) and melanoma (LOX IMVI) cell lines .

HY-107426

Verrucarin A Muconomycin A	Apoptosis Reactive Oxygen Species	Cancer
Verrucarin A (Muconomycin A), a Type D macrocyclic mycotoxin derived from the pathogen fungus Myrothecium verrucaria, is an inhibitor of protein synthesis. Verrucarin A inhibits growth of leukemia cell lines and activates caspases and apoptosis and inflammatory signaling in macrophages. Verrucarin A effectively increased the phosphorylation of p38 MAPK and diminished the phosphorylation of ERK/Akt. Verrucarin A caused cell cycle deregulation through the induction of p21 and p53 .

HY-N3210

Nb-Demethylechitamine	Others	Cancer
Nb-Demethylechitamine is an alkaloid isolated from the methanol extract of Alstonia rostrata twigs. Nb-Demethylechitamine has in vitro cytotoxic activity against several human cancer cell lines, including human myeloid leukemia HL-60, liver cancer SMMC-7721, lung cancer A-549, breast cancer MCF-7, and colon cancer SW480 cells .

HY-132231

FD223	PI3K Apoptosis	Cancer
FD223 is a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. FD223 displays high potency (IC₅₀=1 nM) and good selectivity over other isoforms (IC₅₀s of 51 nM, 29 nM and 37 nM, respectively for α, β and γ). FD223 exhibits efficient inhibition of the proliferation of acute myeloid leukemia (AML) cell lines by suppressing p-AKT Ser473 thus causing G1 phase arrest during the cell cycle. FD223 has potential for the research of leukemia such as AML .

HY-116971

DCG066	Histone Methyltransferase Apoptosis	Cancer
DCG066 is an inhibitor of lysine methyltransferase G9a. DCG066 can bind directly to G9a and inhibit methyltransferase activity in vitro. DCG066 decreases di-methylation levels of histone H3 lysine 9 (H3K9Me2), inhibits cell proliferation and induces cell apoptosis. DCG066 displays low cytotoxicity in leukemia cell lines with high levels of G9a expression, including K562 .

HY-158968

MMs02943764	MDM-2/p53	Cancer
MMs02943764 is a 1,2,4-triazole derivative with anticancer activity. MMs02943764 has significant antiproliferative effects on multiple cancer cell lines. PAC, a structural analog of MMs02943764, has significant cytotoxicity against the leukemia cell line K562 (IC₅₀=35.264 μM), reduces the degradation of p53 by inhibiting Mdm2 and Pirh2, and induces K562 cell cycle arrest .

HY-149470

MOZ-IN-3	Histone Acetyltransferase	Cancer
MOZ-IN-3 (Compound 6j) is a KAT6A (MOZ) acetyltransferase inhibitor (IC₅₀: 30 nM). MOZ-IN-3 has antitumor activity against four different myeloid leukemia cell lines (HL-60, U937, SKNO-1, K562). MOZ-IN-3 has favorable metabolic stability and pharmacokinetics .

HY-13518

Piceatannol Maximum Cited Publications 19 Publications Verification Astringenin; trans-Piceatannol	Syk Autophagy Apoptosis Endogenous Metabolite	Cancer
Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI) . Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties . Piceatannol induces apoptosis in DLBCL cell lines . Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells .

HY-19619

m-3M3FBS 5 Publications Verification	Phospholipase Apoptosis	Cancer
m-3M3FBS is a potent phospholipase C (PLC) activator. m-3M3FBS stimulates superoxide generation in human neutrophils, upregulates intracellular calcium concentration, and stimulates inositol phosphate generation in various cell lines. m-3M3FBS induces monocytic leukemia cell apoptosis .

HY-149497

HDAC6-IN-19	HDAC	Cancer
HDAC6-IN-19 (Compound 14g) is a HDAC6 inhibitor (IC₅₀: 2.68 nM). HDAC6-IN-19 also inhibits HDAC1, HDAC2 and HDAC3 with IC₅₀s of 61.6 nM, 98.7 nM and 103 nM. HDAC6-IN-19 potently inhibits multiple cancer cell proliferation, including leukemia, colon cancer, melanoma, and breast cancer cell lines .

Cat. No.	Product Name	Target	Research Area

HY-P5327

r8 Bid BH3	Bcl-2 Family	Others
r8 Bid BH3 is a biological active peptide. (The Bid BH3 is a pro-apoptotic member of the 'BH3-only' subset of BCL-2 family proteins that constitute a critical control point in apoptosis. r8BIDBH3 is lethal to human leukemia cell lines that expresse Bcl-2. The Bcl-2 antagonists may have the potential to be efficacious in cancer therapy. Poly-D-arginine (d-isomer as denoted by rrrrrrrr) is fused to the Bid BH3 peptide to facilitate cellular uptake of the peptide.)

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks